Press Releases

Search Press Releases:

• All News
• 2020
• 2019
• 2018
• 2017
• 2016
• 2015
• 2014
• 2013
• 2012
• 2011
• 2010

Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder

April 22, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

April 4, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

March 25, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

March 18, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

March 12, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

March 11, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces New European Use Patent for TNX-601

March 7, 2019 • 4:15 PM EST

Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder

March 1, 2019 • 5:41 PM EST

Tonix Pharmaceuticals Announces Share Repurchase Program

March 1, 2019 • 4:00 PM EST

Tonix Pharmaceuticals Announces New Board Member, James Treco

February 19, 2019 • 4:30 PM EST

• « Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• ...32
• Next »